International: +1-347-960-6455
Adoption of Advanced Regulatory Approaches by Drug Developers to Mark the Growth in Pancreatic Cancer Therapeutics Pipeline

According to a new research report Pancreatic Cancer Therapeutics - Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, pancreatic cancer currently exhibits a strong pipeline with 144 therapeutic candidates.

Pancreatic Cancer Therapeutics Pipeline Insights

Pancreatic cancer is identified as the formation of tumor due to development of malignant cells in the pancreas. There are two main forms of the disease, namely endocrine and exocrine tumors. Exocrine tumors, also known as adenocarcinomas, is the common type of pancreatic cancer and forms in the pancreas ducts; whereas, endocrine tumors, also known as neuroendocrine tumors, are less common and most often benign in nature.

Diabetes, smoking, obesity, age, pancreatitis, and family history of tumors are some of the risk factors associated with pancreatic cancer. The disease can be diagnosed by radiological examinations, clinical examinations, and laboratory tests, including biopsy. For detailed diagnosis, healthcare providers might also perform magnetic resonance imaging (MRI), contrast-enhanced multi-detector computed tomography (MD-CT), and magnetic resonance cholangiopancreatography (MRCP).

The pipeline of pancreatic cancer is robust and consists of 144 drugs, that are currently in the Phase III, Phase II, Phase I, Pre-clinical, and Discovery stages of development. Also, majority of the pipeline products are currently in the Phase I stage of clinical studies.

Insights into Pipeline Segments

According to the research findings, majority of the pancreatic cancer therapeutics in the pipeline are being developed for intravenous and oral route of administrations. It has been observed that the intravenous route of medication is convenient and ensures that the entire administered dose reaches the systemic circulation immediately. Also, oral route of administration is available in delayed or rapid release formulation, is associated with less risk of systemic infections, and has inexpensive nature. Further, administration of pancreatic cancer therapeutics through intravenous and oral route have shown promising results in the clinical studies.

Positive Clinical Trial Results are Expected to Drive Pancreatic Cancer Therapeutics Pipeline Expansion

The companies developing therapeutics for the treatment of pancreatic cancer have shown positive clinical results in the various phases of drug development. For instance, AstraZeneca PLC published the interim results of the Phase II trial evaluating the combination of acalabrutinib and pembrolizumab for the treatment of pancreatic cancer. As per the results of the trial, the combination of two drugs showed a favorable benefit/risk profile for the patient.

Technological Advancements Play a Pivotal Role in the Pancreatic Cancer Therapeutics Development

Some of pharmaceutical companies engaged in the development of drugs for pancreatic cancer are leveraging their technologies for the drug development. These technologies play an important role in the drug development; thereby, helping the companies to develop more specific and effective targeted therapies. For instance, Helix BioPharma Corp. is utilizing its DOS47 technology, which is based on the principle of using an enzyme to catalyze the metabolism of an endogenous substrate molecule in order to yield metabolites with potential therapeutic benefits. Similarly, Propanc Biopharma Inc. is using its Pancreatic Proenzyme Therapy Platform, which is designed to help the patients to fight against cancer, using natural elements found within the organism.

Browse Detailed Report at:

Strategic Advancements Drive the Development of Pancreatic Cancer Therapeutics

In the wake of various strategic developments taking place in the pancreatic cancer therapeutics pipeline, in April 2018, CBT Pharmaceuticals and CrystalGenomics Inc. entered into a partnership agreement to co-develop combination therapy of CBT-501 and CG200745 across immune-oncology indications, including pancreatic cancer.
Similarly, in November 2018, Eleison Pharmaceuticals Inc. and Rafa Laboratories Ltd. signed an agreement. Under the terms of the agreement, Rafa Laboratories Ltd. received exclusive rights to commercialize glufosfamide in Israel. Moreover, Eleison Pharmaceuticals Inc. was subjected to receive future royalties from Rafa Laboratories Ltd., under the terms of this agreement.

Designation Granted by Regulatory Bodies to Accelerate the Development Process of Pancreatic Cancer Therapeutics

Companies are actively seeking designation grants to accelerate the process of drug development. For instance, the U.S. Food and Drug Administration (FDA) granted Fast-Track and Orphan Drug Designation to FibroGen Inc.’s pemrevlumab for the treatment of pancreatic cancer in March 2018 and June 2017, respectively.

Some of the key players involved in the development of pancreatic cancer therapeutics include Novartis AG, Pfizer Inc., AstraZeneca PLC, FibroGen Inc., Eleison Pharmaceuticals Inc., Rafa Laboratories Ltd., CBT Pharmaceuticals, CrystalGenomics Inc., Propanc Biopharma Inc., Helix BioPharma Corp., AB Science S.A, Halozyme Therapeutics Inc., and Sumitomo Dainippon Pharma Co. Ltd.

Pancreatic Cancer Therapeutics Pipeline Analysis

  • By Phase
  • By Route of Administration
  • By Company

The report comprises detailed pipeline analysis of therapeutics being developed for the treatment of pancreatic cancer. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the development of pancreatic cancer therapeutics. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in this report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to pancreatic cancer.